Rare Tumours in Children and Adolescents (STEP)

NCT05773651 · tracked via the Priya Life Science Germany tracker

Sponsor

University Hospital Tuebingen

Phase

Observational

Started

2023-01-11

Last updated

2024-10-01

Condition(s) studied

Rare Diseases

Investigational drug(s) / intervention(s)

Data collection

Data collection: The data collection includes, among other things: Diagnosis of the rare tumor (pathological findings/ reference pathological findings), full name, birth date, gender, clinical registry inclusion and exclusion criteria met - yes / no, signed declaration of consent-yes / no, if yes: date of signature

Study summary

The aim of the STEP registry is to collect and evaluate experience and data on the diagnosis and treatment of rare childhood tumors in order to use the knowledge gained to improve the treatment prospects for our patients. The rarity of a disease should not be a disadvantage for the young patients.

Eligibility

Sex

ALL

Min age

1 Day

Max age

18 Years

Healthy volunteers

Inclusion Criteria: * Diagnosis of a rare solid tumor * Age at diagnosis: Neonatal period to 18 years (In the case of young adults, registration in the database and/or referral to advisory contact persons within the framework of the competence network can take place upon request and after declaration of consent.) * Information, education, written consent of the patient or the guardian * Not recorded in any of the existing clinical studies/ registers of the German Society for Pediatric Oncology and Hematology (GPOH) Exclusion Criteria: * Registration of the tumor diagnosis in a prospective therapy study/ another clinical registry of the GPOH * Lack of information, explanation and/or written consent of the patient or the legal guardian.

Primary outcome measure(s)

Event-free survival — 5 years
Period between study entry and failure of induction therapy, recurrence or death from any cause is measured.

Trial sites (1)

Facility	City	Region	Status
University Hospital Tübingen	Tübingen	Germany	Recruiting

More University Hospital Tuebingen trials in Germany

A Strong Start in Life - ELAS 2.0: A Digital Learning Program to Promote a Healthy Pregnancy and Early Child Protection Starting soon

Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults Recruiting

PREG - Offspring: Investigation of Children From Mothers With and Without Gestational Diabetes Recruiting

The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4 Recruiting

Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac Recruiting

Other trials for the same condition

Genetic Causes of Discrepant Clinic in Monogenic Twins Recruiting

Diagnostic Value of Exome/ Genome Sequencing, Conventional Methods in Rare Diseases and Familial Tumor Syndromes Recruiting

Genome-based Management of Patients in Precision Medicine (Ge-Med) Towards a Genomic Health Program Recruiting

Evaluation of HEArt invoLvement in Patients With FABRY Disease Recruiting

Solving Riddles Through Sequencing Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05773651 on ClinicalTrials.gov ↗ ← All trials in Germany